{"id":47197,"date":"2022-08-11T16:02:20","date_gmt":"2022-08-11T14:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-9-5m-series-c-funding-round-to-expand-brain-health-and-wellness-offerings\/"},"modified":"2022-08-11T16:02:20","modified_gmt":"2022-08-11T14:02:20","slug":"interaxon-inc-muse-announces-9-5m-series-c-funding-round-to-expand-brain-health-and-wellness-offerings","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-9-5m-series-c-funding-round-to-expand-brain-health-and-wellness-offerings\/","title":{"rendered":"Interaxon Inc. (Muse\u00ae) Announces $9.5M Series C Funding Round To Expand Brain Health and Wellness Offerings"},"content":{"rendered":"
\n

\nThe Funding Will Support New Research Initiatives Around Brain Health and Increasing Accessibility to The Company\u2019s EEG Technology Platform<\/i>\n<\/p>\n

TORONTO–(BUSINESS WIRE)–Interaxon Inc. ( Muse\u00ae<\/a>), the leading consumer neurotechnology company, announced that it has closed an oversubscribed $9.5M USD Series C funding round through a non-brokered private placement. The round was led by BDC Capital, Alabaster (family office of Sunny Vu, founder of Misfit), and Export Development Canada, along with new institutional investors including Phyto Partners, Iter Investments, Intretech(HK) Co, and The Clavis Foundation. Co-founder Ariel Garten also participated in the round. As a result of the strong market interest, the Company has opened an allotment for additional oversubscription, with a second (final) close planned by the end of Q3 for strategic investment.\n<\/p>\n

\nWith this funding, Interaxon aims to enrich its leading brain health platform through launching an integrated wellness membership model and further research and validation of an industry-first feature tracking longitudinal changes in the brain. Interaxon will also support expanding offerings for third-party developers, researchers, clinicians and other strategic partnerships.\n<\/p>\n

\n\u201cAt Muse, we\u2019re passionate about supporting the neuroscience research community,\u201d said Ariel Garten, co-founder of Interaxon. \u201cWe are excited for the value this funding will unlock, including the development and validation of an industry first, user-friendly EEG measurement showing changes in brain age that can provide value in a variety of research and clinical settings.\u201d\n<\/p>\n

\nThe Membership Shift: Increasing Accessibility to Brain Health Tools<\/b>\n<\/p>\n

\nExpanding their brain health platform offerings, Muse\u2019s first-ever brain performance measurement will allow users to compare themselves to various groups across the broader population, and against their own historical values over time. A recent discovery from Muse\u2019s R&D team has showcased exciting new patterns in their extensive EEG database with strong indications of brain health. The Company aims to leverage these patterns through the development of groundbreaking metrics that will provide users meaningful insights into brain health and lifestyle factors (i.e. meditation, sleep, alcohol, stress, exercise, diet, etc.) that affect it. These personalized insights along with other new biosensor trend reports will roll out later this year, and will be included in the new membership program.\n<\/p>\n

\nThe new membership model, launching in Q1 2023, provides a lower-cost entry for customers to try advanced wearable EEG technology without the high upfront cost. Members will have access to participate in community research initiatives, continuous expert support, ongoing content updates, headband replacements and new device models, when available. This offering is strategic to Muse\u2019s ongoing commitment to be a long-term wellness partner, providing new and innovative ways for users to gain deeper insight into their brain health and overall well-being.\n<\/p>\n

\nInvestor Quote:<\/i> <\/i>Lally Rementilla, Managing Partner of BDC Capital said, \u201cWe\u2019re proud to support Muse in their pursuit of continually providing users with not only a deeper understanding of their brain health and overall wellbeing, but interventions that support them when they need it. It\u2019s a privilege to partner with Muse as they continue to expand their product offerings and extensive IP portfolio.\u201d<\/i><\/b>\n<\/p>\n

\nInvestor Quote: Larry Schnurmacher, Managing Partner at Phyto Partners, said, \u201cThe innovation happening in and around neuro-wellness and brain health space is accelerating and we are privileged to support Muse in their mission to not only provide a wider audience offering, but also in providing the research community and SDK partners with tools to further the transformation of this space.\u201d<\/i><\/b>\n<\/p>\n

\nThe Company will also invest in key strategic partnerships including SDK and research partnerships opportunities that leverage their world leading EEG technology platform in the development of data-driven studies and systems that will support the advancement of neuroscience, neurotechnology and brain health at large.\n<\/p>\n

\nTo learn more about Interaxon\u2019s investment opportunities contact Derek Luke, CEO of Interaxon, at derek@interaxon.ca<\/a>.\n<\/p>\n

\nAbout Interaxon Inc.<\/b>:\n<\/p>\n

\nInteraxon is a late-stage venture company in the neurotechnology space, with a brain and biosensor platform of hardware and software products, a sophisticated data-cloud infrastructure, popular consumer and licensable B2B products, the largest database of brain data in the world, and an IP fortress with several fundamental granted brain, biosignal, VR and AR patents with early priority dates. Interaxon is currently completing a second investment round to support converting the company’s current up-front cost model to an integrated subscription model.\n<\/p>\n

\nInteraxon is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.\n<\/p>\n

\nMilestones we\u2019re excited about:<\/b>\n<\/p>\n